Triplet combinations containing a proteasome inhibitor are a standard of
The novel triplet IRD (ixazomib, lenalidomide, dexamethasone) has been approved in
Published: 15 January 2021 Survival benefit of ixazomib, lenalidomide and
Objectives: In the absence of head-to-head comparisons across relapsed/refractory multiple myeloma (RRMM) treatments following the approval of the oral proteasome inhibitor ixazomib, in combination with lenalidomide and dexamethasone (IRd), we conducted an indirect comparison of the efficacy of IRd relative to several RRMM therapies using
The number of planned doses per cycle was 3 for ixazomib, 21 for lenalidomide, and 4 for dexamethasone
Each cycle lasted 28 days
This multi-centric, retrospective, observational study conducted by the treating physicians evaluated the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in 155 patients who received
11
Twenty-three patients discontinued induction for stem cell transplantation (SCT)
ixazomib, lenalidomide and dexamethasone) must be commenced at the same time and Ixazomib cannot be added in as an additional agent in the treatment of patients who have already previously commenced treatment with lenalidomide and dexamethasone
[1] Ixazomib is the first oral second-generation proteasome inhibitor that was approved by the FDA
This demonstrated a median progression free survival (PFS) of 20
It belongs to a class of drugs known as proteasome inhibitors
This Treatment Guide contains information about ixazomib, a drug used in the treatment of myeloma
Ixazomib is approved for use in combination with lenalidomide and dexamethasone (IRd) for patients with multiple myeloma (MM) who received at least one previous therapy
Ixazomib is available as 2